Supplementary Figure 15 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Supplementary Figure 15. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to chemo-immunotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with advanced/metastatic PD-L1 intermediate (1-49%) NSCLC, according to ATM mutation status. (G) Objective response rate, (H) progression-free survival, and (I) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with advanced/metastatic PD-L1 high (≥50%) NSCLC, according to ATM mutation status.